PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat.
Kainic acid-induced multifocal status epilepticus in the rat is a model of medically intractable complex partial seizures and neurotoxicity. The exact mechanisms of kainic acid epileptogenic and neurotoxic effects are unknown, but enhanced glutamate release seems to be an important factor. PNU-151774E ((S)-(+)-2-(4-(3-fluorobenzyloxy) benzylamino) propanamide, methanesulfonate) is a broad-spectrum new anticonvulsant with Na+ channel-blocking and glutamate release inhibiting properties. We have examined the effect of pretreatment with this compound on both seizure activity and hippocampal neuronal damage induced by systemic injection of kainic acid in rats. Lamotrigine, a recently developed anticonvulsant with similar glutamate release inhibitory properties, was tested for comparison, together with diazepam as reference standard, on the basis of its anticonvulsant and neuroprotectant properties in this animal model. PNU-151774E, lamotrigine (10, 30 mg/kg; i.p.) and diazepam (20 mg/kg; i.p.) were administered 15 min before kainic acid (10 mg/kg; i.p.). In the vehicle-treated group, kainic acid injection caused status epilepticus in 86% of animals. Hippocampal neuronal cell loss was 66% in the CA4 hippocampal area at 7 days after kainic acid administration. Diazepam inhibited both seizures and neurotoxicity. Lamotrigine reduced hippocampal neuronal cell loss at both doses, even when it did not protect from seizures, although it showed a trend toward protection. On the other hand PNU-151774E protected from both hippocampal neurodegeneration and status epilepticus. Thus, these data support the concept that seizure prevention and neuroprotection might not be tightly coupled. Glutamate release inhibition may play a major role in neuroprotection, but an additional mechanism(s) of action might be relevant for the anticonvulsant activity of PNU-151774E in this model.
Maj
R
R
CNS Preclinical Research, Pharmacia and Upjohn SpA, Nerviano, (MI), Italy. roberto.maj@eu.pnu.com
Fariello
R G
RG
Ukmar
G
G
Varasi
M
M
Pevarello
P
P
McArthur
R A
RA
Salvati
P
P
D000409:Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D001596:Benzylamines / Q000627:therapeutic use*; D003975:Diazepam / Q000627:therapeutic use; D004827:Epilepsy / Q000139:chemically induced / Q000188:drug therapy*; D006624:Hippocampus / Q000187:drug effects* / Q000502:physiology; D007608:Kainic Acid; D000077213:Lamotrigine; D008297:Male; D018696:Neuroprotective Agents / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D014227:Triazines / Q000627:therapeutic use
D000927:Anticonvulsants; D001596:Benzylamines; D018696:Neuroprotective Agents; D014227:Triazines; C092797:safinamide; D000409:Alanine; D003975:Diazepam; D007608:Kainic Acid; D000077213:Lamotrigine